Currently, the combination of an immune checkpoint inhibitor (ICI) and vascular endothelial growth factor (VEGF) inhibitors, atezolizumab (Atez) and bevacizumab (Bev), has been used as a first-line treatment for advanced-stage HCC [8]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.